DDInter1506 DDInter704
Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Pramlintide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Everolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etacrynic acid
Etacrynic acid {u} (Compound) upregulates {v} (Gene) CTSL
CTSL {u} (Gene) is upregulated by {v} (Compound) Everolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Grepafloxacin
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conjugated estrogens
Conjugated estrogens {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etacrynic acid
Etacrynic acid {u} (Compound) downregulates {v} (Gene) HMG20B
HMG20B {u} (Gene) is upregulated by {v} (Compound) Everolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conjugated estrogens
Conjugated estrogens {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dicyclomine
Dicyclomine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Everolimus
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Pramlintide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Everolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid (Compound) upregulates CTSL (Gene) and CTSL (Gene) is upregulated by Everolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid (Compound) downregulates HMG20B (Gene) and HMG20B (Gene) is upregulated by Everolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Everolimus (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Everolimus (Compound)